ANP32A
Acidic leucine-rich nuclear phosphoprotein 32 family member A
Protein Summary
Implicated in a number of cellular processes, including proliferation, differentiation, caspase-dependent and caspase-independent apoptosis, suppression of transformation (tumor suppressor), inhibition of protein phosphatase 2A, regulation of mRNA trafficking and stability in association with ELAVL1, and inhibition of acetyltransferases as part of the INHAT (inhibitor of histone acetyltransferases) complex. Plays a role in E4F1-mediated transcriptional repression.
- ENST00000465139
- ENSP00000417864
- ENSG00000140350
- C15orf1
- LANP
- MAPM
- PHAP1
- LANP
- MAPM
- PP32
- HPPCn
- PHAP1
- PHAPI
- I1PP2A
- C15orf1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 1 | ||
PubMedID | 0.97 | ||
transcription factor binding site profile | 0.86 | ||
co-expressed gene | 0.72 | ||
microRNA | 0.7 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 215.9 (req: < 5)
Gene RIFs: 53 (req: <= 3)
Antibodies: 452 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 215.9 (req: >= 5)
Gene RIFs: 53 (req: > 3)
Antibodies: 452 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 5
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0